# Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

> **NCT04683250** · PHASE1,PHASE2 · RECRUITING · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 244 (estimated)

## Conditions studied

- RET-altered Non Small Cell Lung Cancer
- RET-altered Solid Tumors

## Interventions

- **DRUG:** TAS0953/HM06
- **DRUG:** TAS0953/HM06

## Key facts

- **NCT ID:** NCT04683250
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-16
- **Primary completion:** 2030-03
- **Final completion:** 2031-03
- **Target enrollment:** 244 (ESTIMATED)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04683250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04683250, "Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04683250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*